CAPRICOR THERAPEUTICS INC (CAPR)
Health Care · cell and exosome-based therapeutics for rare genetic diseases · NASDAQ
Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for Duchenne muscular dystrophy treatment.
What CAPRICOR THERAPEUTICS INC does
Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases with significant unmet medical need. The company's lead product, Deramiocel, is a cell therapy comprised of cardiosphere-derived cells (CDCs) designed to treat Duchenne muscular dystrophy (DMD) by addressing cardiac and skeletal muscle complications through immunomodulatory, anti-inflammatory, and anti-fibrotic activities. Deramiocel is currently under FDA review with a PDUFA target action date of August 22, 2026. The company is also advancing its exosome platform (StealthX) for infectious diseases, monogenic diseases, and other potential indications through collaborations with the NIH, NIAID, Johns Hopkins, and others.
Themes: cell therapy / regenerative medicine, Duchenne muscular dystrophy (DMD), exosome therapeutics, rare genetic diseases, immunomodulation
Fundamentals
- Price$6.29 as of 2026-08-21 close
- Market cap$366M as of 2026-08-21
- 1-year return-10.4% 2025-08-21 close $7.02 → 2026-08-21 close $6.29
- P/En/a negative earnings
- Net margin-181.7% as of 2026-08-24
- ROE-59.3% as of 2026-08-24
- Debt / equity0.02 as of 2026-08-24
- Beta0.34 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CAPR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CAPRICOR THERAPEUTICS INC looks technically
CAPRICOR THERAPEUTICS INC (CAPR) is trading 72.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 16 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day low about 16 trading days ago. It is 84.4% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 72.9% below its 200-day average, the long-term trend line — a long-term downtrend | -72.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.31 | $16.31 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.20 | $23.20 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 16 trading days ago — a "death cross", a bearish long-term signal | 16 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with sellers in control | 46.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 35.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.73 to $8.29) — its "stochastic" reading is 56 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 56.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $40.37 | $40.37 |
|---|---|---|
| From the 52-week high | it is 84.4% below its 52-week high (its highest price of the past year) | -84.4% |
| Above the 52-week low | it is 112.5% above its 52-week low (its lowest price of the past year) | +112.5% |
| Below the 52-week high | it is 84.4% below its highest point of the past year | 84.4% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $3500.00 (set on 2007-10-24) | $3500.00 |
| Given back of the 52-week move | over the past year its closes ranged ($3.85 to $35.34), and it has recovered only a small part of its fall from last year’s high — 8% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $23.31 to $24.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.8% |
| From the all-time high | it is 99.8% below its all-time high | -99.8% |
| Nearest price level | it is trading 0.9% above a support level at $6.23 — a price it turned at twice since 2025-05-09, most recently on 2025-07-21. Since 2024-08-21 it has 2 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.9% |
| All-time low | its lowest closing price on record is $0.88 (set on 2020-03-12) | $0.88 |
| Above the all-time low | it is 614.8% above its all-time low | +614.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 86% of the past ~6 months) | 86th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.38 between its high and its low — about 22.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.38 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.43 and $8.29 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.43 – $5.36 – $8.29 |
| Typical daily range (% of price) | its price moves about 22.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 22.0% |
| Stretch from the 200-day average | it is trading 12.2 daily ranges below its 200-day average price (72.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.98× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 140.0% since the prior reading | +140.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.22 toward buy |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 4.0% below the previous close 1 session ago and has not traded back through the level it left behind at 7.98 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.0% |
| Gap filled | a 3.5% gap up opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -21.18% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 70.5 percentage points (the stock lost 68.2% while the market gained 2.3%) | -70.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 81.8 percentage points (the stock lost 78.7% while the market gained 3.1%) | -81.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 89.0 percentage points (the stock lost 77.9% while the market gained 11.1%) | -89.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 30.9 percentage points (the stock lost 10.4% while the market gained 20.5%) | -30.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 73% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 56.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -72.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 58% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $15.04 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | -58.2% |
|---|
Price levels it has turned at before
CAPR last closed at $6.29 on 2026-08-21. Since 2024-08-21 it has turned at 2 prices below its last close and 11 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.23 | Support | 0.9% below the last close | turned there twice · 2025-05-09 to 2025-07-21 |
| $6.02 | Support | 4.3% below the last close | turned there three times · 2025-06-20 to 2025-10-17 |
| $8.09 | Resistance | 28.5% above the last close | turned there twice · 2025-04-09 to 2025-10-02 |
| $9.48 | Resistance | 50.7% above the last close | turned there twice · 2025-06-03 to 2025-08-08 |
| $11.61 | Resistance | 84.6% above the last close | turned there three times · 2025-03-18 to 2025-06-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Analyst price target recently RAISED · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.78 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$10.50 range $2.00 – $28.00; median $6.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CAPR
- Consensus EPS estimate-$0.38 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["FDA regulatory approval risk: Deramiocel's BLA is under FDA review with PDUFA target date of August 22, 2026; approval is not certain and delays or rejection would significantly impact commercialization prospects.","Commercial and litigation risk: Company is engaged in litigation with Nippon Shinyaku regarding Deramiocel distribution rights; outcome could materially affect the company's ability to commercialize Deramiocel in the United States.","Liquidity and financing risk: Company is unprofitable with significant ongoing losses; ability to fund operations depends on successful commercialization of Deramiocel or obtaining additional financing, which may be difficult given competitive environment and lack of approved products."]
What changed in the latest 10-Q
AI-assisted comparison of CAPR's 10-Q filed 2026-05-13 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'Item 1A, "Risk Factors" in this Quarterly Report' in the forward-looking statements disclaimer (newer filing)
- Added phrase 'Capricor' as separate term in references definition with clarification about subsidiary (older filing had different phrasing)
- Added statement about litigation: 'If approved and if our litigation against NS Pharma, Inc. and Nippon Shinyaku Co., Ltd. (collectively, "NS") is successful, we intend to commercialize Deramiocel in the United States directly or through distributors' (newer filing)
- Added detailed description of Deramiocel's mechanism via exosomes: 'These effects are mediated in part by exosomes secreted by CDCs that contain bioactive molecules, including microRNAs and other signaling factors' (newer filing)
- Added StealthX™ branded exosome platform section with detailed description of EVs, collaborations with NIH, NIAID, JHU, Department of Defense, U.S. Army Institute of Surgical Research, and CSMC (newer filing)
- Added statement: 'Our current strategy is focused on advancing these programs through collaborations and partnerships that may provide additional development resources and capital to support potential clinical development' (newer filing)
- Added PDUFA target action date of August 22, 2026 (newer filing)
- Added information about FDA interactions post-December 2024 submission and CRL issuance (newer filing includes reference to existing BLA submission pathway)
- Removed:
- Removed 'clinical-stage' descriptor from company description (older filing stated 'clinical-stage biotechnology company'; newer filing states 'biotechnology company')
- Removed reference to 'Capricor, Inc., our wholly-owned subsidiary' separate definition (phrasing consolidated in newer filing)
- Removed discussion of partnership plans: 'we intend and plan to commercialize Deramiocel in the United States and Japan with our partner, Nippon Shinyaku Co., Ltd.' (older filing)
- Removed 'Regulatory Progress and BLA Pathway' subsection header and related regulatory timeline details (older filing provided extensive 2024-2025 regulatory history including pre-BLA meeting, rolling submission, Priority Review, mid-cycle review, PLI, CRL, and Type A meeting outcomes)
- Removed detailed HOPE-3 trial description including randomization details, manufacturing cohorts (LA and San Diego facilities), DSMB futility analysis in 2023, topline data expectation for Q4 2025 (older filing)
- Removed statement about primary endpoint (PUL v2.0) and secondary endpoint (LVEF by cMRI) confirmation (older filing)
- Removed statement about 800+ infusions to ~150 DMD patients (older filing)
- Reworded:
- Changed 'treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration' to 'treatment of Duchenne muscular dystrophy ("DMD"), a rare genetic disorder characterized by progressive muscle degeneration' (newer filing uses 'rare genetic disorder' and 'progressive')
- Changed 'other diseases with high unmet medical needs' to 'other diseases with significant unmet medical need' (newer filing uses 'significant' instead of 'high')
- Changed 'developing Deramiocel and our other product candidates including our exosomes platform technology' to 'development of our lead product candidate, Deramiocel...as well as to advancing our exosome-based platform technologies' (newer filing reorders and emphasizes 'lead' status)
- Changed 'We do not have any products approved for commercial sale' to 'We currently have no products approved for commercial sale' (newer filing adds 'currently')
- Changed description of CDC source from 'healthy donor hearts' to 'qualified donated human hearts' (newer filing)
- Changed 'for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy' to description encompassing broader mechanism addressing 'cardiac and skeletal muscle complications associated with DMD' (newer filing)
- Notes:
- The older filing text appears truncated at the end ('safety data from the trial have been regularly reported to the FDA, and no significant safety signals have been observed. Across our programs, we have administered more than 800 infusions to approximately 150 DMD patients with Deramiocel continuing to demonstrate a strong and consistent saf') making full comparison of trailing content impossible
- The newer filing text also appears truncated at the end ('Phase 2') making complete comparison of the pipeline section impossible
- Structural reorganization occurred: older filing organized content as 'Regulatory and Clinical Update' followed by 'Regulatory Progress and BLA Pathway'; newer filing presents content differently with Company Overview followed by separate Cell Therapy and Exosomes Platform sections
Risk Factors
- Added:
- Added forward-looking statement about regulatory developments involving FDA review of Deramiocel (CAP-1002) as lead product candidate (filed 2026-05-13)
- Added forward-looking statement about litigation against Nippon Shinyaku Co., Ltd and NS Pharma, Inc. regarding distribution of Deramiocel (filed 2026-05-13)
- Added forward-looking statement about ability to market and sell Deramiocel through distribution channels other than NS (filed 2026-05-13)
- Added comma after 'potential' in forward-looking statement identifier list (filed 2026-05-13)
- Removed:
- Removed generic statement 'our ability to market any of our products' and replaced with more specific language about Deramiocel and NS distribution (filed 2026-05-13)
- Removed reference to 'our lead product candidate, Deramiocel' from the regulatory status bullet point context - moved to separate FDA bullet (filed 2026-05-13)
- Reworded:
- Reordered bullet points: FDA regulatory developments and litigation items now appear earlier in the list (filed 2026-05-13 vs 2025-11-10)
- Changed 'the timing and results of regulatory meetings and inspections, and the ability to obtain regulatory approvals or otherwise bring products to market' from standalone bullet to part of broader FDA review statement (filed 2026-05-13)
- Modified regulatory status bullet to remove timing/inspection language, focusing on designation maintenance for Deramiocel specifically (filed 2026-05-13)
- Notes:
- Table of Contents page numbers differ: Item 1A Risk Factors listed as page 44 in newer filing vs page 48 in older filing
- Financial data sections are truncated/garbled in both versions, limiting full comparison of balance sheet changes
- Newer filing appears to be for period ended March 31, 2026; older filing for period ended September 30, 2025
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 6 sells ($2M) — 2 selling insiders
- Last 180 days0 buys · 10 sells ($4M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-25. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CAPR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CAPR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 7,816,197
- Reported value $237,612,374
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CAPR had 15,984,662 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CAPR had 27.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.06 days to cover at the same settlement.
- Reported short interest (shares) 15,984,662
- Short interest (% of shares outstanding) 27.5%
- Prior settlement (shares) 15,578,639
- Reported change 2.61%
- Days to cover (reported) 2.06
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sarepta Therapeutics (SRPT)
- PTC Therapeutics (PTCT)
- Solid Biosciences (SLDB)
- Reata Pharmaceuticals (RETA)
- Pfizer (PFE)
- Vertex Pharmaceuticals (VRTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CAPR vs…
CAPR ranks in…
Frequently asked questions
What does CAPRICOR THERAPEUTICS INC (CAPR) do?
Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases with significant unmet medical need. The company's lead product, Deramiocel, is a cell therapy comprised of cardiosphere-derived cells (CDCs) designed to treat Duchenne muscular dystrophy (DMD) by addressing cardiac and skeletal muscle complications through immunomodulatory, anti-inflammatory, and anti-fibrotic activities.
What sector is CAPRICOR THERAPEUTICS INC (CAPR) in?
CAPRICOR THERAPEUTICS INC (CAPR) is classified in the Health Care sector. Its industry is cell and exosome-based therapeutics for rare genetic diseases. It trades on NASDAQ.
Who are CAPRICOR THERAPEUTICS INC's (CAPR) competitors?
Notable peers of CAPRICOR THERAPEUTICS INC (CAPR) include Sarepta Therapeutics, PTC Therapeutics, Solid Biosciences, Reata Pharmaceuticals and Pfizer. This peer set is informational only — not financial advice.
Is CAPRICOR THERAPEUTICS INC (CAPR) overbought or oversold right now?
CAPRICOR THERAPEUTICS INC (CAPR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CAPR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.